ten23 health Expands its Sterile Drug Product Manufacturing Site at Visp, Switzerland
ten23 health is expanding its sterile drug product manufacturing site at Visp, Switzerland to enlarge cold storage and visual inspections capacity and add clean rooms.
ten23 health, a global contract development and manufacturing organization (CDMO), announced on March 28, 2022 that it is expanding swissfillon’s manufacturing site in Visp, Switzerland. The site was acquired in October 2021 from swissfillon and will be expanded into an adjacent building with an additional 1000 square meters of cleanroom space.
The expansion will also increase the company’s cold storage and visual inspections capacity and add 1000 square meters of cleanroom space for additional services such as device assembly and secondary packaging by the end of 2022. This expansion is in addition to its 4000 square meters of lab and office space for its operations in Basel, Switzerland, which was launched in September 2021.
“Only five months ago, swissfillon joined ten23 health. This first expansion of the footprint in Visp is a strong commitment to our location in the Valais as well as Switzerland and a testimonial of the competent and experienced team at Visp,” commented Prof. Dr. Hanns-Christian Mahler, CEO of ten23 health, in a press release. “Furthermore, it is an important step in our long-term strategy to expand out manufacturing capacity for complex sterile dosage forms for our customers and their patients.”
Source: ten23 health
